Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer
M Takeda, I Okamoto, K Nakagawa - Lung Cancer, 2015 - Elsevier
Objectives Three epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)–
afatinib, erlotinib, and gefitinib–are available for the treatment of patients with EGFR …
afatinib, erlotinib, and gefitinib–are available for the treatment of patients with EGFR …
[HTML][HTML] First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III …
Background The phase III, randomized, open-label ENSURE study (NCT01342965)
evaluated first-line erlotinib versus gemcitabine/cisplatin (GP) in patients from China …
evaluated first-line erlotinib versus gemcitabine/cisplatin (GP) in patients from China …
[HTML][HTML] First-generation EGFR-TKI plus chemotherapy versus EGFR-TKI alone as first-line treatment in advanced NSCLC with EGFR activating mutation: a systematic …
Q Wu, W Luo, W Li, T Wang, L Huang, F Xu - Frontiers in Oncology, 2021 - frontiersin.org
Objective The aim of this meta-analysis was to evaluate efficacy and toxicity of epidermal
growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in combination with …
growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in combination with …
Afatinib in the treatment of EGFR mutation-positive NSCLC–a network meta-analysis
Objectives Epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung
cancer (NSCLC) is a specific lung cancer subtype characterized by sensitivity to treatment …
cancer (NSCLC) is a specific lung cancer subtype characterized by sensitivity to treatment …
[HTML][HTML] Efficacy and safety of epidermal growth factor receptor (EGFR) inhibitors plus antiangiogenic agents as first-line treatments for patients with advanced EGFR …
F Chen, N Chen, Y Yu, J Cui - Frontiers in Oncology, 2020 - frontiersin.org
Background: Tyrosine kinase inhibitors (TKIs) are standard treatment options for non-small
cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations …
cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations …
[HTML][HTML] Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line …
E Bria, M Milella, F Cuppone, S Novello, A Ceribelli… - Annals of oncology, 2011 - Elsevier
Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) are
effective as first-line treatment of advanced non-small-cell lung cancer patients with EGFR …
effective as first-line treatment of advanced non-small-cell lung cancer patients with EGFR …
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567) …
T Seto, T Kato, M Nishio, K Goto, S Atagi… - The lancet …, 2014 - thelancet.com
Background With use of EGFR tyrosine-kinase inhibitor monotherapy for patients with
activating EGFR mutation-positive non-small-cell lung cancer (NSCLC), median progression …
activating EGFR mutation-positive non-small-cell lung cancer (NSCLC), median progression …
A randomized Phase 2 study to compare erlotinib with or without bevacizumab in previously untreated patients with advanced non–small cell lung cancer with EGFR …
Background This study evaluated whether an addition of bevacizumab to erlotinib improves
clinical outcomes in patients with advanced EGFR‐mutated non–small cell lung cancer …
clinical outcomes in patients with advanced EGFR‐mutated non–small cell lung cancer …
[HTML][HTML] Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
L Paz-Ares, EH Tan, K O'Byrne, L Zhang, V Hirsh… - Annals of …, 2017 - Elsevier
ABSTRACT Background In LUX-Lung 7, the irreversible ErbB family blocker, afatinib,
significantly improved progression-free survival (PFS), time-to-treatment failure (TTF) and …
significantly improved progression-free survival (PFS), time-to-treatment failure (TTF) and …
Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
CK Lee, L Davies, YL Wu, T Mitsudomi… - JNCI: Journal of the …, 2017 - academic.oup.com
Background: We performed an individual patient data meta-analysis to examine the impact
of first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) …
of first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) …